title: Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential Class Improvement From Intramyocardial Channels.
abstract: BACKGROUND
  Percutaneous transmyocardial laser revascularisation (PTMR) is a proposed catheter-based therapy for refractory angina pectoris when bypass surgery or angioplasty is not possible. We undertook a randomised trial to assess the safety and efficacy of this technique.
  
  
  METHODS
  221 patients with reversible ischaemia of Canadian Cardiovascular Society angina class III (61%) or IV (39%) and incomplete response to other therapies were recruited from 13 centres. Patients were randomly assigned PTMR with a holmium:YAG laser plus continued medical treatment (n=110) or continued medical treatment only (n=111). The primary endpoint was the exercise tolerance at 12 months. Analyses were by intention to treat.
  
  
  RESULTS
  11 patients died and 19 withdrew; 92 PTMR-group and 99 medical-treatment-group patients completed the study. Exercise tolerance at 12 months had increased by a median of 89.0 s (IQR -15 to 183) with PTMR compared with 12.5 s (-67 to 125) with medical treatment only (p=0.008). On masked assessment, angina class was II or lower in 34.1% of PTMR patients compared with 13.0% of those medically treated. All indices of the Seattle angina questionnaire improved more with PTMR than with medical care only. By 12 months there had been eight deaths in the PTMR group and three in the medical treatment group, with similar survival in the two groups.
  
  
  CONCLUSIONS
  PTMR was associated with increased exercise tolerance time, low morbidity, lower angina scores assessed by masked reviewers, and improved quality of life. Although there is controversy about the mechanism of action, and the contribution of the placebo effect cannot be quantified, this unmasked study suggests that this palliative procedure provides some clinical benefits in the defined population of patients.
authors.affiliation: Massachusetts General Hospital, Boston, MA 02114, USA. oesterle.stephen@mgh.harvard.edu
authors.forename: S N
authors.initials: SN
authors.lastname: Oesterle
authors.forename: T A
authors.initials: TA
authors.lastname: Sanborn
authors.forename: N
authors.initials: N
authors.lastname: Ali
authors.forename: J
authors.initials: J
authors.lastname: Resar
authors.forename: S R
authors.initials: SR
authors.lastname: Ramee
authors.forename: R
authors.initials: R
authors.lastname: Heuser
authors.forename: L
authors.initials: L
authors.lastname: Dean
authors.forename: W
authors.initials: W
authors.lastname: Knopf
authors.forename: P
authors.initials: P
authors.lastname: Schofield
authors.forename: G L
authors.initials: GL
authors.lastname: Schaer
authors.forename: G
authors.initials: G
authors.lastname: Reeder
authors.forename: R
authors.initials: R
authors.lastname: Masden
authors.forename: A C
authors.initials: AC
authors.lastname: Yeung
authors.forename: D
authors.initials: D
authors.lastname: Burkhoff
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D010352:Patient Dropouts; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents